Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LJPC La Jolla Pharmaceutical (LJPC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About La Jolla Pharmaceutical Stock (NASDAQ:LJPC) 30 days 90 days 365 days Advanced Chart Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get LJPC alerts:Sign Up Key Stats Today's Range N/A50-Day Range$3.12▼$6.2252-Week Range N/AVolume66,708 shsAverage Volume158,476 shsMarket Capitalization$155.11 millionP/E Ratio51.84Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewLa Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.Read More… 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Receive LJPC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address LJPC Stock News HeadlinesInnoviva to Participate in the UBS Global Healthcare ConferenceNovember 12, 2024 | finance.yahoo.comAurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of GrowthNovember 8, 2024 | theglobeandmail.com[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.November 21, 2024 | Crypto Swap Profits (Ad)Aurinia stock jumps 14% on Q3 earnings, restructuring announcementNovember 7, 2024 | msn.comInnoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024October 15, 2024 | finance.yahoo.comLongboard Pharmaceuticals Shares Hit All-Time High on Takeover by LundbeckOctober 14, 2024 | marketwatch.comH. Lundbeck to Buy Longboard Pharmaceuticals for $2.6 Billion -- UpdateOctober 14, 2024 | marketwatch.comInnoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company ProgressMay 8, 2024 | finance.yahoo.comSee More Headlines LJPC Stock Analysis - Frequently Asked Questions How were La Jolla Pharmaceutical's earnings last quarter? La Jolla Pharmaceutical (NASDAQ:LJPC) posted its earnings results on Monday, May, 16th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.01 by $0.16. The biopharmaceutical company earned $10.43 million during the quarter, compared to analysts' expectations of $13.10 million. La Jolla Pharmaceutical had a net margin of 8.54% and a negative trailing twelve-month return on equity of 5.46%. What other stocks do shareholders of La Jolla Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), El Pollo Loco (LOCO), Intercept Pharmaceuticals (ICPT), Bristol-Myers Squibb (BMY), Exelixis (EXEL), Sarepta Therapeutics (SRPT) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings5/16/2022Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LJPC CUSIPN/A CIK920465 Webwww.lajollapharmaceutical.com Phone(617) 715-3600Fax858-626-2851Employees61Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.12 Trailing P/E Ratio51.84 Forward P/E RatioN/A P/E GrowthN/ANet Income$19.66 million Net Margins8.54% Pretax Margin8.64% Return on Equity-5.46% Return on Assets4.00% Debt Debt-to-Equity RatioN/A Current Ratio4.02 Quick Ratio3.52 Sales & Book Value Annual Sales$75.72 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow7.95 Book Value($2.94) per share Price / BookN/AMiscellaneous Outstanding Shares24,937,000Free Float15,885,000Market Cap$155.11 million OptionableOptionable Beta2.39 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:LJPC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding La Jolla Pharmaceutical Please log in to your account or sign up in order to add this asset to your watchlist. Share La Jolla Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.